Compare BCBP & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | CNTN |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.5M | 178.5M |
| IPO Year | 2005 | 2021 |
| Metric | BCBP | CNTN |
|---|---|---|
| Price | $8.66 | $1.88 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.95 | N/A |
| AVG Volume (30 Days) | 272.3K | ★ 735.7K |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $1.66 |
| 52 Week High | $11.71 | $5.27 |
| Indicator | BCBP | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 42.22 |
| Support Level | $8.50 | $1.75 |
| Resistance Level | $8.84 | $2.40 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 96.21 | 27.07 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.